

Original Investigation | Geriatrics

Association Between Sleep Duration and Cognitive Decline

Yanjun Ma, BA; Lirong Liang, MD; Fanfan Zheng, PhD; Le Shi, MD; Baoliang Zhong, MD; Wuxiang Xie, PhD

Abstract

IMPORTANCE An association between sleep duration and the trajectory of cognitive decline has not been conclusively demonstrated.

OBJECTIVE To investigate the association between sleep duration and cognitive decline by a pooled analysis of 2 nationally representative aging cohorts.

DESIGN, SETTING, AND PARTICIPANTS A pooled cohort study using data from waves 4 to 8 (2008-2009 to 2016-2017) in the English Longitudinal Study of Ageing and waves 1 to 3 (2011 to 2015) in the China Health and Retirement Longitudinal Study in a population-based setting. Participants were 2 randomly enrolled cohorts comprising 28 756 individuals living in England who were 50 years or older and those living in China who were 45 years or older.

EXPOSURE Self-reported sleep duration per night according to face-to-face interviews.

MAIN OUTCOMES AND MEASURES Global cognitive *z* scores were calculated according to immediate and delayed recall test, an animal fluency test, the serial sevens test, an intersecting pentagon copying test, and a date orientation test.

RESULTS Data were analyzed from 20 065 participants, including 9254 from the English Longitudinal Study of Ageing (mean [SD] age, 64.6 [9.8] years; 55.9% [5174 of 9254] women; median follow-up duration, 8 [interquartile range, 6-8] years) and 10 811 from the China Health and Retirement Longitudinal Study (mean [SD] age, 57.8 [9.0] years; 50.2% [5425 of 10 811] men; median follow-up duration, 4 [interquartile range, 4-4] years). During 100 000 person-years of follow-up, global cognitive *z* scores in individuals with 4 hours or less (pooled β = -0.022; 95% Cl, -0.035 to -0.009 SD per year; *P* = .001) and 10 hours or more (pooled β = -0.033; 95% Cl, -0.054 to -0.011 SD per year; *P* = .003) of sleep per night declined faster than in the reference group (7 hours per night) after adjusting for a number of covariates. An inverted U-shaped association between sleep duration and global cognitive decline was also observed.

CONCLUSIONS AND RELEVANCE In this pooled cohort study, an inverted U-shaped association between sleep duration and global cognitive decline was found, indicating that cognitive function should be monitored in individuals with insufficient (\leq 4 hours per night) or excessive (\geq 10 hours per night) sleep duration. Future studies are needed to examine the mechanisms of the association between sleep duration and cognitive decline.

JAMA Network Open. 2020;3(9):e2013573. doi:10.1001/jamanetworkopen.2020.13573

Key Points

Question What is the association between sleep duration and cognitive decline in the general aging population?

Findings During 100 000 personyears of follow-up in this pooled cohort study of 28 756 individuals, global cognitive function in individuals with extreme sleep duration (\leq 4 or \geq 10 hours per night) declined statistically significantly faster than in the reference group (7 hours per night) after adjusting for covariates. An inverted U-shaped association between sleep duration and global cognitive decline was also observed.

Meaning The inverted U-shaped association indicates that cognitive function should be monitored in individuals with insufficient or excessive sleep duration.

Invited Commentary

Supplemental content

Author affiliations and article information are listed at the end of this article.

Open Access. This is an open access article distributed under the terms of the CC-BY License.

Introduction

The proportion of older people has increased rapidly in recent decades such that 12% of the global population in 2015 was 60 years or older.¹ By 2050, this proportion is projected to be greater than one-fifth of the population.¹ Consequently, the number of older adults with cognitive impairment and dementia is increasing rapidly.² Dementia is one of the most common and serious disorders in later life. It is responsible for a large proportion of disability and mortality in older people and imposes a huge burden of long-term care for families and society.³ No effective therapies are available for treating dementia; therefore, the development of dementia prevention strategies has become a priority.^{4,5} During the long preclinical phase of dementia, accelerated cognitive decline is regarded as a cardinal marker. Thus, the identification of risk factors for cognitive decline is of great significance for dementia prevention.

Previous studies have reported a strong association between sleep and cognitive function in older adults.⁶ Although a number of cohort studies⁷⁻²⁴ have examined whether baseline sleep duration was associated with cognitive decline and incident dementia, the results were inconsistent. Some cohort studies⁷⁻¹¹ observed sleep duration to be statistically significantly associated with cognitive decline and incident dementia, whereas other studies¹²⁻²⁴ did not reach this conclusion. However, the sample sizes of most previous studies^{11,12,14-16,18-22,24} were small. In addition, the magnitude of the association between sleep duration, especially extreme sleep duration (\leq 4 or \geq 10 hours per night), and various cognitive domains is unclear. Therefore, a large cohort study is needed to explore the association between sleep duration and the trajectory of cognitive decline.

The English Longitudinal Study of Ageing (ELSA)²⁵ and the China Health and Retirement Longitudinal Study (CHARLS)²⁶ are both nationally representative studies of aging cohorts with multiwave data sets, including cognitive assessments and large sample sizes. These studies enabled investigation of the longitudinal association between baseline sleep duration and consequent cognitive decline. Hence, in the present study, we sought to assess the association between sleep duration and the trajectory of subsequent cognitive decline by pooling and analyzing data from these 2 cohorts.

Methods

Study Population

We affirm that all procedures contributing to this pooled cohort study comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Declaration of Helsinki,²⁷ as revised in 2013. The data were derived from 2 community-based nationally representative longitudinal cohort studies conducted in the United Kingdom and China (waves 4-8 [2008-2009 to 2016-2017] in the ELSA and waves 1 to 3 [2011 to 2015] in the CHARLS) in a population-based setting, which were approved by the London Multicenter Research Ethics Committee and the Peking University Institutional Review Board, respectively. All participants in the 2 cohorts provided written informed consent. Deidentified data from the 2 cohorts were used in this pooled analysis. This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.

eFigure 1 in the Supplement shows flowcharts describing the participant selection process for this study. The ELSA sample comprised 11 050 individuals 50 years or older who were participants in the Health Survey for England, which randomly enrolled individuals living in England based on postcode.^{25,28,29} The ELSA commenced in 2002-2003 (wave 1), and follow-up assessments were conducted every 2 years until 2016-2017 (wave 8). Because sleep duration was first included in the assessment during wave 4 of the ELSA, wave 4 (2008-2009) was regarded as the baseline of the present study, and we assessed data from the follow-up assessments conducted during waves 5 to 8. The CHARLS cohort included 17 706 randomly selected Chinese residents 45 years or older who were enrolled via multistage probability sampling.²⁶ The first wave of data collection in the CHARLS took

place in 2011, and follow-up surveys were conducted at 2-year intervals until 2015. Because the participant sleep duration data were collected during the first wave, data from wave 1 (2011 [baseline]) to wave 3 (2015) of the CHARLS were used in the present study. This study included data from 20 065 participants, 9254 from the ELSA and 10 811 from the CHARLS, for whom the baseline data sets were complete and at least 1 remeasurement of cognitive functioning had been conducted (eFigure 1 in the Supplement).

Sleep Duration

Baseline sleep duration was self-reported without any given categories in face-to-face interviews. Participants were asked to report the "number of hours of sleep on an average week night" (in the ELSA) and to respond to the question "During the past month, how many hours of actual sleep did you get at night (average hours for one night)?" (in the CHARLS). The participants were divided into 7 groups according to sleep duration (\leq 4, 5, 6, 7, 8, 9, or \geq 10 hours per night) for the analyses (eMethods in the Supplement).

Cognitive Assessment

Cognitive assessment was conducted in all waves and included the 3 aspects of memory, executive function, and orientation. The memory and orientation function tests were the same for the 2 cohorts, whereas the executive function assessment differed.

The memory assessment task comprised immediate and delayed word recall for 10 unrelated words. The memory score was the sum of words that were successfully recollected in the immediate and delayed word recall tasks, separately, and ranged from 0 to 20. The orientation test comprised 4 questions regarding the day of the week, the month, the date of the month, and the year. One point was given for each correct answer. In the ELSA, individuals were asked to name as many animals as they could in 1 minute, and the number of animal names was counted as the executive score. In the CHARLS, executive function was assessed using the serial sevens test, in which the participant counts backward from 100 in increments of 7 (5 successive counts, with 1 point given for each correct answer), and by copying intersecting pentagons, in which the participant is asked to observe and draw a picture of 2 overlapping pentagons (3 points were given for a successful drawing and 0 points for an unsuccessful drawing). The executive score was the sum of these 2 tests and ranged from 0 to 8. Both the reliability and the validity of these tests have been well documented³⁰⁻³³ (eMethods in the Supplement).

The *z* Scores of the cognitive function test data were generated to compare across tests. Specifically, each test score was standardized according to the baseline score by subtracting the mean and dividing by the SD. For example, given a baseline mean memory score of 10.6889994 and SD of 3.4863824 in the ELSA, a memory score of 12 points at any wave in the ELSA would be converted into a standardized memory *z* score as follows: (12 – 10.6889994) / 3.4863824. Therefore, an individual with original memory scores of 12, 11, 8, 9, and 9 at waves 4 to 8 in the ELSA had corresponding *z* scores of 0.38, 0.09, –0.77, –0.48, and –0.48, respectively. The *z* score for global cognitive function was calculated by averaging the *z* scores for the 3 tests and restandardizing to baseline according to the mean and SD of the baseline global cognitive *z* scores. This approach has been widely adopted to calculate *z* scores of global cognitive function.³⁰⁻³⁴

Covariates

Covariates that might confound the association between sleep duration and cognitive function in the analyses included sex, age (in years), body mass index (calculated as weight in kilograms divided by height in meters squared), systolic blood pressure (in mm Hg), level of education, Center for Epidemiologic Studies Depression (CES-D) Scale score, cohabitation status, current smoking, alcohol consumption, diabetes, and self-reported history of coronary heart disease, stroke, cancer, chronic lung disease, or asthma. In the CHARLS, a high level of education was defined as completion of at least senior level of high school; in the ELSA, it was defined as at least the level 3 National Vocational

Qualification or the General Certificate of Education Advanced Level, which is equivalent to senior high school. Cohabitation status indicated whether or not the participant currently lived alone. The ELSA used the 8-item version of the CES-D Scale to measure depressive symptoms. ^{35,36} Each item was scored with a 0 or 1, with a maximum score of 8. As in previous studies, ^{36,37} participants scoring 4 or more were defined as having depressive symptoms. At the CHARLS baseline, a 10-item version of the CES-D was used to assess depressive symptoms. ³⁸ Each item was scored from 0 (rarely or none of the time) to 3 (most or all of the time), for a summed score ranging from 0 to 30. According to prior validation studies, ^{38,39} a score of 12 or higher was used to define depressive symptoms. Alcohol consumption was defined as drinking at least once per week over the previous year. Hypertension was defined as systolic blood pressure of at least 140 mm Hg, diastolic blood pressure of at least 90 mm Hg, and/or self-reported treatment of hypertension with antihypertensive medication. Diabetes was defined as self-reported physician-diagnosed diabetes or current use of antidiabetic therapy. Chronic disease measures included self-reported physician-diagnosed cancer, chronic lung disease, and asthma (eMethods in the Supplement).

Statistical Analysis

The results are presented as number (percentage) for discrete variables and as mean (SD) or median (interquartile range [IQR]) for continuous variables. First, data were analyzed at the cohort level according to the following uniform protocol. In cross-sectional analyses, analysis of covariance was used to examine the association between hours of sleep per night and cognitive function at baseline after adjusting for the covariates mentioned previously. The results are presented as least-squares means with 95% CIs of cognitive *z* scores compared with the reference group (7 hours per night).

The multiple measures of cognitive function in individual participants constituted repeatedmeasures data. Linear mixed models were used to evaluate the longitudinal association between baseline sleep duration and consequent cognitive decline (SD per year) during follow-up, incorporate all available follow-up data on cognitive function, account for the correlations between repeated measures conducted in individual participants, and handle missing data. In these models, personal identification numbers were used to identify repeated measures of cognitive function, and both the slope and the intercept were fitted as random effects to account for different rates of cognitive decline during the follow-up assessments and interindividual differences at baseline, respectively. Models included baseline sleep duration per night, time (in years since baseline), baseline sleep duration by time interaction, and the covariates mentioned above. The regression coefficient of the interaction term indicated a differential change in cognitive *z* scores (SD per year) compared with the reference group (7 hours per night).

Pooled analyses were then conducted using random-effects meta-analyses, which take study heterogeneity into account, to generate pooled effect estimates and 95% CIs. The extent of variability across the studies that was attributable to heterogeneity beyond sampling error was estimated using the *I*² statistic.

Both cross-sectional and longitudinal analyses were stratified by sex as sensitivity analyses. Statistical analyses were 2-sided, with a=.05 as the threshold for statistical significance, and were performed using SAS version 9.4 (SAS Institute Inc) and Stata version 11 (StataCorp LLC).

Data Availability

The data sets from the ELSA and the CHARLS are freely available to all bonafide researchers. The UK Data Service and the CHARLS research team may be contacted to gain access to the ELSA⁴⁰ and CHARLS⁴¹ data, respectively. The data can also be obtained on request from the corresponding author.

Results

Baseline Characteristics and Sample Size

Of 28 756 individuals who participated in the baseline survey, 20 065 had a complete baseline data set and at least 1 reassessment of cognitive function (eFigure 1 in the Supplement), including 9254 from the ELSA (mean [SD] age, 64.6 [9.8] years; 55.9% [5174 of 9254] women; median follow-up duration, 8 [IQR, 6-8] years) and 10 811 from the CHARLS (mean [SD] age, 57.8 [9.0] years; 50.2% [5425 of 10 811] men; median follow-up duration, 4 [IQR, 4-4] years). Baseline sleep duration and the participant covariates are listed in **Table 1**.

Baseline Sleep Duration and Cognitive Scores Cross-sectional Analyses

As summarized in **Table 2**, the results derived from the 2 cohorts were comparable. The adjusted least-squares means of the global cognitive *z* scores among individuals reporting 8, 9, 10 or more, or 4 hours or fewer of sleep per night were statistically significantly lower than in the reference group (7 hours per night). Similarly, a statistically significant association between longer (8, 9, or \geq 10 hours) or shorter (\leq 4 hours) sleep duration and lower baseline scores in the 3 cognitive domains was observed except for that between sleep duration of 9 or 10 hours or more and memory function (eTables 1, 2, and 3 in the Supplement). **Figure 1** shows the results from the pooled analyses, in which

ELSA (n = 9254)CHARLS (n = 10 811)Men (n = 4080)Women (n = 5174)Men (n = 5425)Women (n = 5386)Age, mean (SD), y6.4.8 (0.2)6.4.4 (10.2)5.8.9 (8.9)5.6. (9.0)Steep duration per night, h9142 (3.5)300 (5.8)679 (12.5)868 (16.1)5305 (7.5)489 (9.5)696 (12.8)727 (13.5)6305 (7.5)489 (9.5)696 (12.8)727 (13.5)66305 (7.5)489 (9.5)696 (12.8)727 (13.5)6305 (7.5)489 (9.5)1132 (20.9)1113 (20.7)71418 (34.8)1593 (30.8)1132 (20.9)1132 (20.9)9190 (4.7)262 (5.1)209 (3.9)193 (3.6)21064 (1.6)93 (1.8)221 (4.1)219 (4.1)80 dy mass index, mean (SD)28.3 (4.6)28.5 (5.7)23.1 (3.5)24.2 (3.8)Blood pressure, mean (SD), mm Hg552 (11.0)74.8 (10.8)76.6 (12.3)75.4 (11.8)Ystolic135.2 (16.9)132.2 (18.5)130.3 (20.3)129.0 (21.6)Diatolic75.9 (11.10)74.8 (10.8)76.6 (12.3)75.4 (11.8)High level of education2053 (50.3)1854 (35.8)932 (17.2)569 (10.6)Center for Epidemiologic Studies Depression cale score, median (URN)00 (9.8)84 (17.1)1094 (20.2)1628 (30.2)Living alone2053 (57.2)236 (57.4)234 (57.7)234 (57.7)234 (57.7)Depressive symptoms400 (9.8)<		No. (%)						
Characteristic (n = 4080) (n = 5174) (n = 5425) (n = 5386) Age, mean (SD), y 64.8 (9.2) 64.4 (10.2) 58.9 (8.9) 56.6 (9.0) Step duration per night, h 142 (3.5) 300 (5.8) 69 (12.8) 727 (13.5) § 4 0.05 (7.5) 489 (9.5) 696 (12.8) 727 (13.5) § 4 0.035 (20.0) 1197 (21.0) 1141 (21.2) § 4 0.035 (20.0) 1132 (20.0) 1132 (20.9) § 7 1152 (28.2) 1402 (27.1) 1291 (23.8) 1125 (20.9) § 9 150 (28.0) 132 (20.0) 133 (20.7) 133 (20.7) § 10 152 (28.2) 1402 (27.1) 1291 (23.8) 1125 (20.9) § 10 130 (20.7) 29 (3.9) 133 (20.7) 130 (20.7) [10 130 (20.7) 29 (4.1) 20 (4.1) 20 (4.1) [10 93 (18.5) 130.3 (20.3) 12.9 (21.6) [10 10 7.6 (11.8) 7.6 (11.8) 7.6 (11.8) [20 10.01,01 7.6 (12.3) 7.6		ELSA (n = 925	54)	CHARLS (n = 10811)				
Steep duration per night, h 44 (3.5) 300 (5.8) 679 (12.5) 868 (16.1) 5 305 (7.5) 489 (9.5) 696 (12.8) 727 (13.5) 6 809 (19.8) 1035 (20.0) 1197 (22.1) 1141 (21.2) 7 1418 (34.8) 1593 (30.8) 1132 (20.9) 1113 (20.7) 8 1152 (28.2) 1402 (27.1) 1291 (23.8) 1125 (20.9) 9 190 (4.7) 262 (5.1) 209 (3.9) 193 (3.6) 210 64 (1.6) 93 (1.8) 221 (4.1) 219 (4.1) Body mass index, mean (SD) ^a 28.3 (4.6) 28.5 (5.7) 23.1 (3.5) 24.2 (3.8) Biot pressure, mean (SD), mm Hg	Characteristic							
s4 142 (3.5) 300 (5.8) 679 (12.5) 868 (16.1) 5 305 (7.5) 489 (9.5) 696 (12.8) 727 (13.5) 6 809 (19.8) 1035 (20.0) 1197 (22.1) 1141 (21.2) 7 1418 (34.8) 1593 (30.8) 1132 (20.9) 1113 (20.7) 8 1152 (28.2) 1402 (27.1) 1291 (23.8) 1125 (20.9) 9 190 (4.7) 262 (5.1) 209 (3.9) 193 (3.6) s10 64 (1.6) 93 (1.8) 211 (4.1) 219 (4.1) Body mass index, mean (SD) ^a 28.3 (4.6) 28.5 (5.7) 23.1 (3.5) 24.2 (3.8) Blood pressure, mean (SD) m Hg 5ystolic 135.2 (16.9) 132.2 (18.5) 130.3 (20.3) 129.0 (21.6) Diastolic 75.9 (11.0) 74.8 (10.8) 76.6 (12.3) 75.4 (11.8) High level of education 2053 (50.3) 1854 (35.8) 932 (17.2) 569 (10.6) Certer for Epidemiologic Studies Depression 0 (0-1) 1 (0-2) 6 (3-10) 8 (4.13) Depressive symptoms 400 (9.8)	Age, mean (SD), y	64.8 (9.2)	64.4 (10.2)	58.9 (8.9)	56.6 (9.0)			
5 305 (7.5) 489 (9.5) 696 (12.8) 727 (13.5) 6 809 (19.8) 1035 (20.0) 1197 (22.1) 1141 (21.2) 7 1418 (34.8) 1593 (30.8) 1132 (20.9) 1113 (20.7) 8 1152 (28.2) 1402 (27.1) 1291 (23.8) 1125 (20.9) 9 190 (4.7) 262 (5.1) 209 (3.9) 193 (3.6) eddy mass index, mean (SD) ^a 28.3 (4.6) 28.5 (5.7) 23.1 (3.5) 24.2 (3.8) Blood pressure, mean (SD), mm Hg 5ystolic 135.2 (16.9) 132.2 (18.5) 130.3 (20.3) 129.0 (21.6) Diastolic 75.9 (11.0) 74.8 (10.8) 76.6 (12.3) 75.4 (11.8) High level of education 2053 (50.3) 1854 (35.8) 932 (17.2) 569 (10.6) Certer for Epidemiologic Studies Depression 0 (0-1) 1 (0-2) 6 (3-10) 8 (4-13) Depressive symptoms 400 (9.8) 884 (17.1) 1094 (20.2) 1628 (30.2) Living alone 565 (13.8) 729 (14.1) 4014 (74.0) 413 (7.7) Alcohol consumption at leas	Sleep duration per night, h							
6 809 (19.8) 1035 (2.0) 1197 (22.1) 1141 (21.2) 7 1418 (34.8) 1593 (30.8) 1132 (20.9) 1113 (20.7) 8 1152 (28.2) 1402 (27.1) 1291 (23.8) 1125 (20.9) 9 100 (4.7) 262 (5.1) 209 (3.9) 193 (3.6) 210 64 (1.6) 93 (1.8) 221 (4.1) 219 (4.1) Body mass index, mean (SD) ^a 28.3 (4.6) 28.5 (5.7) 23.1 (3.5) 24.2 (3.8) Blood pressure, mean (SD), mm Hg 5 5 130.3 (20.3) 129.0 (21.6) Diastolic 75.9 (11.0) 74.8 (10.8) 76.6 (12.3) 75.4 (11.8) High level of education 2053 (50.3) 1854 (35.8) 932 (17.2) 569 (10.6) Center for Epidemiologic Studies Depression Scale score, median (IQR) 0 (0-1) 1 (0-2) 6 (3-10) 8 (4-13) Depressive symptoms 400 (9.8) 884 (17.1) 1094 (20.2) 1628 (30.2) Living alone 965 (23.7) 1936 (37.4) 426 (7.9) 634 (11.8) Current smoking 565 (13.8)	≤4	142 (3.5)	300 (5.8)	679 (12.5)	868 (16.1)			
71418 (34.8)1593 (30.8)1132 (20.9)1113 (20.7)801152 (28.2)1402 (27.1)1291 (23.8)1125 (20.9)9100262 (5.1)209 (3.9)193 (3.6)1064 (1.6)93 (1.8)221 (4.1)219 (4.1)20mass index, mean (SD) ^a 28.3 (4.6)28.5 (5.7)23.1 (3.5)24.2 (3.8)8pressure, mean (SD), mm Hg135.2 (16.9)130.3 (20.3)129.0 (21.6)Diatolic75.9 (11.0)74.8 (10.8)76.6 (12.3)75.4 (11.8)Diatolic75.9 (11.0)74.8 (10.8)932 (17.2)699 (10.6)Cimet for Epidemiologic Studies Depression0 (0-1)1 (0-2)6 (3-10)8 (4-13)Cimet for Epidemiologic Studies Depression0 (0.1)1 (0-2)6 (3-10)634 (11.8)Cimet for Spintoms265 (3.7)1396 (37.4)1494 (74.0)413 (7.7)Cimet for Spintoms265 (13.8)729 (14.1)4014 (74.0)413 (7.7)Cimet sonking65 (13.8)729 (14.1)4014 (74.0)413 (7.7)Cimet sonking2350 (57.6)2485 (47.3)1745 (32.2)160 (3.0)Firet son2350 (57.6)2485 (47.3)1745 (32.2)160 (3.0)Cimet sonking355 (8.7)245 (4.7)249 (7.7)39 (13.7)Cimet sonking356 (8.7)245 (4.7)249 (7.9)334 (6.2)Cimet sonking356 (8.7)245 (4.7)249 (7.9)34 (6.2)Cimet sonking356 (8.7)245 (4.7)249 (7.9) <td< td=""><td>5</td><td>305 (7.5)</td><td>489 (9.5)</td><td>696 (12.8)</td><td>727 (13.5)</td></td<>	5	305 (7.5)	489 (9.5)	696 (12.8)	727 (13.5)			
8 1152 (28.2) 1402 (27.1) 1291 (23.8) 1125 (20.9) 9 190 (4.7) 262 (5.1) 209 (3.9) 193 (3.6) ≥10 64 (1.6) 93 (1.8) 221 (4.1) 219 (4.1) Body mass index, mean (SD) ^a 28.3 (4.6) 28.5 (5.7) 23.1 (3.5) 24.2 (3.8) Blody mass index, mean (SD), mm Hg 5ystolic 135.2 (16.9) 132.2 (18.5) 130.3 (20.3) 129.0 (21.6) Diastolic 75.9 (11.0) 74.8 (10.8) 76.6 (12.3) 75.4 (11.8) High level of education 2053 (50.3) 1854 (35.8) 932 (17.2) 569 (10.6) Center for Epidemiologic Studies Depression Scale score, median (IQR) 0(0.1) 1 (0-2) 6 (3.10) 8 (4.13) Depressive symptoms 400 (9.8) 884 (17.1) 1094 (20.2) 1628 (30.2) Living alone 965 (23.7) 1936 (37.4) 426 (7.9) 634 (11.8) Current smoking 565 (13.8) 729 (14.1) 4014 (74.0) 413 (7.7) Alcohol consumption at least once per week 2654 (65.0) 2445 (47.3) 1745 (32.2) <	6	809 (19.8)	1035 (20.0)	1197 (22.1)	1141 (21.2)			
9 190 (4.7) 262 (5.1) 209 (3.9) 193 (3.6) 210 64 (1.6) 93 (1.8) 221 (4.1) 219 (4.1) Body mass index, mean (SD) ^a 28.3 (4.6) 28.5 (5.7) 23.1 (3.5) 24.2 (3.8) Blood pressure, mean (SD), mm Hg 5 35.2 (16.9) 132.2 (18.5) 130.3 (20.3) 129.0 (21.6) Diastolic 75.9 (11.0) 74.8 (10.8) 76.6 (12.3) 75.4 (11.8) High level of education 2053 (50.3) 1854 (35.8) 932 (17.2) 569 (10.6) Center for Epidemiologic Studies Depression Scale score, median (IQR) 0 (0-1) 1 (0-2) 6 (3-10) 8 (4-13) Living alone 965 (23.7) 1936 (37.4) 426 (7.9) 634 (11.8) Current smoking 565 (13.8) 729 (14.1) 4014 (74.0) 413 (7.7) Alcohol consumption at least once per week 2654 (65.0) 2445 (47.3) 1745 (32.2) 160 (3.0) Hypertension 2350 (57.6) 2682 (51.8) 2035 (37.5) 2033 (37.7) Diabetes 396 (9.7) 338 (6.5) 281 (5.2) 344 (6.2	7	1418 (34.8)	1593 (30.8)	1132 (20.9)	1113 (20.7)			
≥10 64 (1.6) 93 (1.8) 221 (4.1) 219 (4.1) Body mass index, mean (SD) ^a 28.3 (4.6) 28.5 (5.7) 23.1 (3.5) 24.2 (3.8) Blood pressure, mean (SD), mm Hg 5ystolic 130.3 (20.3) 129.0 (21.6) Diastolic 75.9 (11.0) 74.8 (10.8) 76.6 (12.3) 75.4 (11.8) High level of education 2053 (50.3) 1854 (35.8) 932 (17.2) 569 (10.6) Center for Epidemiologic Studies Depression 0 (0-1) 1 (0-2) 6 (3-10) 8 (4-13) Depressive symptoms 400 (9.8) 884 (17.1) 1094 (20.2) 1628 (30.2) Living alone 965 (23.7) 1936 (37.4) 426 (7.9) 634 (11.8) Current smoking 565 (13.8) 729 (14.1) 4014 (74.0) 413 (7.7) Alcohol consumption at least once per week 2654 (65.0) 2445 (47.3) 1745 (32.2) 160 (3.0) Hypertension 2350 (57.6) 288 (51.8) 2035 (37.5) 2033 (37.7) Diabetes 396 (9.7) 338 (6.5) 281 (5.2) 341 (6.2) Coronary heart disease 355 (8.7) 245 (4.7) 524 (9.7) 739 (13.7)	8	1152 (28.2)	1402 (27.1)	1291 (23.8)	1125 (20.9)			
Body mass index, mean (SD) ^a 28.3 (4.6) 28.5 (5.7) 23.1 (3.5) 24.2 (3.8) Blood pressure, mean (SD), mm Hg 135.2 (16.9) 132.2 (18.5) 130.3 (20.3) 129.0 (21.6) Systolic 75.9 (11.0) 74.8 (10.8) 76.6 (12.3) 75.4 (11.8) High level of education 2053 (50.3) 1854 (35.8) 932 (17.2) 569 (10.6) Center for Epidemiologic Studies Depression 0 (0-1) 1 (0-2) 6 (3-10) 8 (4-13) Depressive symptoms 400 (9.8) 884 (17.1) 1094 (20.2) 1628 (30.2) Living alone 965 (23.7) 1936 (37.4) 426 (7.9) 634 (11.8) Current smoking 565 (13.8) 729 (14.1) 4014 (74.0) 413 (7.7) Alcohol consumption at least once per week 2654 (65.0) 2445 (47.3) 1745 (32.2) 160 (3.0) Hypertension 2350 (57.6) 2682 (51.8) 2035 (37.5) 2033 (37.7) Diabetes 396 (9.7) 338 (6.5) 281 (5.2) 34 (6.2) Coronary heart disease 355 (8.7) 245 (4.7) 524 (9.7) 79 (1.3)	9	190 (4.7)	262 (5.1)	209 (3.9)	193 (3.6)			
Blood pressure, mean (SD), mm Hg 332.2 (16.9) 132.2 (18.5) 130.3 (20.3) 129.0 (21.6) Diastolic 75.9 (11.0) 74.8 (10.8) 76.6 (12.3) 75.4 (11.8) High level of education 2053 (50.3) 1854 (35.8) 932 (17.2) 569 (10.6) Center for Epidemiologic Studies Depression 0 (0-1) 1 (0-2) 6 (3-10) 8 (4-13) Depressive symptoms 400 (9.8) 884 (17.1) 1094 (20.2) 1628 (30.2) Living alone 965 (23.7) 1936 (37.4) 426 (7.9) 634 (11.8) Current smoking 565 (13.8) 729 (14.1) 4014 (74.0) 413 (7.7) Alcohol consumption at least once per week 2654 (65.0) 2445 (47.3) 1745 (32.2) 160 (3.0) Hypertension 2350 (57.6) 2682 (51.8) 2035 (37.5) 2033 (37.7) Diabetes 396 (9.7) 338 (6.5) 281 (5.2) 34 (6.2) Coronary heart disease 355 (8.7) 245 (4.7) 524 (9.7) 739 (13.7) Stroke 104 (2.5) 118 (2.3) 103 (1.9) 86 (1.6)	≥10	64 (1.6)	93 (1.8)	221 (4.1)	219 (4.1)			
Systolic135.2 (16.9)132.2 (18.5)130.3 (20.3)129.0 (21.6)Diastolic75.9 (11.0)74.8 (10.8)76.6 (12.3)75.4 (11.8)High level of education2053 (50.3)1854 (35.8)932 (17.2)569 (10.6)Center for Epidemiologic Studies Depression Scale score, median (IQR)0 (0-1)1 (0-2)6 (3-10)8 (4-13)Depressive symptoms400 (9.8)884 (17.1)1094 (20.2)1628 (30.2)Living alone965 (23.7)1936 (37.4)426 (7.9)634 (11.8)Current smoking565 (13.8)729 (14.1)4014 (74.0)413 (7.7)Alcohol consumption at least once per week2654 (65.0)2445 (47.3)1745 (32.2)160 (3.0)Hypertension2350 (57.6)2682 (51.8)2035 (37.5)2033 (37.7)Diabetes396 (9.7)338 (6.5)281 (5.2)334 (6.2)Coronary heart disease355 (8.7)245 (4.7)524 (9.7)739 (13.7)Stroke104 (2.5)118 (2.3)103 (1.9)86 (1.6)Cancer79 (1.9)100 (1.9)27 (0.5)64 (1.2)Chronic lung disease119 (2.9)118 (2.3)618 (11.4)431 (8.0)Asthma254 (6.2)446 (8.6)213 (3.9)138 (2.6)Memory score, mean (SD) or median (IQR) ^b 21.4 (6.8)21.0 (6.6)7 (4-8)5 (3-8)	Body mass index, mean (SD) ^a	28.3 (4.6)	28.5 (5.7)	23.1 (3.5)	24.2 (3.8)			
Diastolic75.9 (11.0)74.8 (10.8)76.6 (12.3)75.4 (11.8)High level of education2053 (50.3)1854 (35.8)932 (17.2)569 (10.6)Center for Epidemiologic Studies Depression0 (0-1)1 (0-2)6 (3-10)8 (4-13)Depressive symptoms400 (9.8)884 (17.1)1094 (20.2)1628 (30.2)Living alone965 (23.7)1936 (37.4)426 (7.9)634 (11.8)Current smoking565 (13.8)729 (14.1)4014 (74.0)413 (7.7)Alcohol consumption at least once per week2654 (65.0)2445 (47.3)1745 (32.2)160 (3.0)Hypertension2350 (57.6)2682 (51.8)2035 (37.5)2033 (37.7)Diabetes396 (9.7)338 (6.5)281 (5.2)334 (6.2)Coronary heart disease355 (8.7)245 (4.7)524 (9.7)739 (13.7)Stroke104 (2.5)118 (2.3)103 (1.9)86 (1.6)Cancer79 (1.9)100 (1.9)27 (0.5)64 (1.2)Chronic lung disease119 (2.9)118 (2.3)618 (11.4)431 (8.0)Asthma254 (6.2)446 (8.6)213 (3.9)138 (2.6)Memory score, mean (SD) or median (IQR) ^b 21.4 (6.8)21.0 (6.6)7 (4-8)5 (3-8)	Blood pressure, mean (SD), mm Hg							
High level of education2053 (50.3)1854 (35.8)932 (17.2)569 (10.6)Center for Epidemiologic Studies Depression0 (0-1)1 (0-2)6 (3-10)8 (4-13)Depressive symptoms400 (9.8)884 (17.1)1094 (20.2)1628 (30.2)Living alone965 (23.7)1936 (37.4)426 (7.9)634 (11.8)Current smoking565 (13.8)729 (14.1)4014 (74.0)413 (7.7)Alcohol consumption at least once per week2654 (65.0)2445 (47.3)1745 (32.2)160 (3.0)Hypertension2350 (57.6)2682 (51.8)2035 (37.5)2033 (37.7)Diabetes396 (9.7)338 (6.5)281 (5.2)334 (6.2)Coronary heart disease355 (8.7)245 (4.7)524 (9.7)739 (13.7)Stroke104 (2.5)118 (2.3)103 (1.9)86 (1.6)Cancer79 (1.9)100 (1.9)27 (0.5)64 (1.2)Chronic lung disease119 (2.9)118 (2.3)618 (11.4)431 (8.0)Asthma254 (6.2)446 (8.6)213 (3.9)138 (2.6)Memory score, mean (SD) or median (IQR) ^b 21.4 (6.8)21.0 (6.6)7 (4-8)5 (3-8)	Systolic	135.2 (16.9)	132.2 (18.5)	130.3 (20.3)	129.0 (21.6)			
Center for Epidemiologic Studies Depression Scale score, median (IQR)0 (0-1)1 (0-2)6 (3-10)8 (4-13)Depressive symptoms400 (9.8)884 (17.1)1094 (20.2)1628 (30.2)Living alone965 (23.7)1936 (37.4)426 (7.9)634 (11.8)Current smoking565 (13.8)729 (14.1)4014 (74.0)413 (7.7)Alcohol consumption at least once per week2654 (65.0)2445 (47.3)1745 (32.2)160 (3.0)Hypertension2350 (57.6)2682 (51.8)2035 (37.5)2033 (37.7)Diabetes396 (9.7)338 (6.5)281 (5.2)334 (6.2)Coronary heart disease355 (8.7)245 (4.7)524 (9.7)739 (13.7)Stroke104 (2.5)118 (2.3)103 (1.9)86 (1.6)Cancer79 (1.9)100 (1.9)27 (0.5)64 (1.2)Chronic lung disease119 (2.9)118 (2.3)618 (11.4)431 (8.0)Asthma254 (6.2)446 (8.6)213 (3.9)138 (2.6)Memory score, mean (SD) or median (IQR) ^b 21.4 (6.8)21.0 (6.6)7 (4-8)5 (3-8)	Diastolic	75.9 (11.0)	74.8 (10.8)	76.6 (12.3)	75.4 (11.8)			
Scale score, median (IQR)400 (9.8)884 (17.1)1094 (20.2)1628 (30.2)Depressive symptoms965 (23.7)1936 (37.4)426 (7.9)634 (11.8)Living alone965 (23.7)1936 (37.4)4014 (74.0)413 (7.7)Current smoking565 (13.8)729 (14.1)4014 (74.0)413 (7.7)Alcohol consumption at least once per week2654 (65.0)2445 (47.3)1745 (32.2)160 (3.0)Hypertension2350 (57.6)2682 (51.8)2035 (37.5)2033 (37.7)Diabetes396 (9.7)338 (6.5)281 (5.2)334 (6.2)Coronary heart disease355 (8.7)245 (4.7)524 (9.7)739 (13.7)Stroke104 (2.5)118 (2.3)103 (1.9)86 (1.6)Cancer79 (1.9)100 (1.9)27 (0.5)64 (1.2)Chronic lung disease119 (2.9)118 (2.3)618 (11.4)431 (8.0)Asthma254 (6.2)446 (8.6)213 (3.9)138 (2.6)Memory score, mean (SD) or median (IQR) ^h 21.4 (6.8)21.0 (6.6)7 (4-8)5 (3-8)	High level of education	2053 (50.3)	1854 (35.8)	932 (17.2)	569 (10.6)			
Living alone965 (23.7)1936 (37.4)426 (7.9)634 (11.8)Current smoking565 (13.8)729 (14.1)4014 (74.0)413 (7.7)Alcohol consumption at least once per week2654 (65.0)2445 (47.3)1745 (32.2)160 (3.0)Hypertension2350 (57.6)2682 (51.8)2035 (37.5)2033 (37.7)Diabetes396 (9.7)338 (6.5)281 (5.2)334 (6.2)Coronary heart disease355 (8.7)245 (4.7)524 (9.7)739 (13.7)Stroke104 (2.5)118 (2.3)103 (1.9)86 (1.6)Cancer79 (1.9)100 (1.9)27 (0.5)64 (1.2)Chronic lung disease119 (2.9)118 (2.3)618 (11.4)431 (8.0)Asthma254 (6.2)446 (8.6)213 (3.9)138 (2.6)Memory score, mean (SD)10.3 (3.4)11.0 (3.5)15.4 (4.6)15.3 (4.8)Executive score, mean (SD) or median (IQR) ^b 21.4 (6.8)21.0 (6.6)7 (4-8)5 (3-8)		0 (0-1)	1 (0-2)	6 (3-10)	8 (4-13)			
Current smoking565 (13.8)729 (14.1)4014 (74.0)413 (7.7)Alcohol consumption at least once per week2654 (65.0)2445 (47.3)1745 (32.2)160 (3.0)Hypertension2350 (57.6)2682 (51.8)2035 (37.5)2033 (37.7)Diabetes396 (9.7)338 (6.5)281 (5.2)334 (6.2)Coronary heart disease355 (8.7)245 (4.7)524 (9.7)739 (13.7)Stroke104 (2.5)118 (2.3)103 (1.9)86 (1.6)Cancer79 (1.9)100 (1.9)27 (0.5)64 (1.2)Chronic lung disease119 (2.9)118 (2.3)618 (11.4)431 (8.0)Asthma254 (6.2)446 (8.6)213 (3.9)138 (2.6)Memory score, mean (SD)10.3 (3.4)11.0 (3.5)15.4 (4.6)15.3 (4.8)Executive score, mean (SD) or median (IQR) ^b 21.4 (6.8)21.0 (6.6)7 (4-8)5 (3-8)	Depressive symptoms	400 (9.8)	884 (17.1)	1094 (20.2)	1628 (30.2)			
Alcohol consumption at least once per week2654 (65.0)2445 (47.3)1745 (32.2)160 (3.0)Hypertension2350 (57.6)2682 (51.8)2035 (37.5)2033 (37.7)Diabetes396 (9.7)338 (6.5)281 (5.2)334 (6.2)Coronary heart disease355 (8.7)245 (4.7)524 (9.7)739 (13.7)Stroke104 (2.5)118 (2.3)103 (1.9)86 (1.6)Cancer79 (1.9)100 (1.9)27 (0.5)64 (1.2)Chronic lung disease119 (2.9)118 (2.3)618 (11.4)431 (8.0)Asthma254 (6.2)446 (8.6)213 (3.9)138 (2.6)Memory score, mean (SD)10.3 (3.4)11.0 (3.5)15.4 (4.6)15.3 (4.8)Executive score, mean (SD) or median (IQR) ^b 21.4 (6.8)21.0 (6.6)7 (4-8)5 (3-8)	Living alone	965 (23.7)	1936 (37.4)	426 (7.9)	634 (11.8)			
Hypertension2350 (57.6)2682 (51.8)2035 (37.5)2033 (37.7)Diabetes396 (9.7)338 (6.5)281 (5.2)334 (6.2)Coronary heart disease355 (8.7)245 (4.7)524 (9.7)739 (13.7)Stroke104 (2.5)118 (2.3)103 (1.9)86 (1.6)Cancer79 (1.9)100 (1.9)27 (0.5)64 (1.2)Chronic lung disease119 (2.9)118 (2.3)618 (11.4)431 (8.0)Asthma254 (6.2)446 (8.6)213 (3.9)138 (2.6)Memory score, mean (SD) or median (IQR) ^h 21.4 (6.8)21.0 (6.6)7 (4-8)5 (3-8)	Current smoking	565 (13.8)	729 (14.1)	4014 (74.0)	413 (7.7)			
Diabetes396 (9.7)338 (6.5)281 (5.2)334 (6.2)Coronary heart disease355 (8.7)245 (4.7)524 (9.7)739 (13.7)Stroke104 (2.5)118 (2.3)103 (1.9)86 (1.6)Cancer79 (1.9)100 (1.9)27 (0.5)64 (1.2)Chronic lung disease119 (2.9)118 (2.3)618 (11.4)431 (8.0)Asthma254 (6.2)446 (8.6)213 (3.9)138 (2.6)Memory score, mean (SD)10.3 (3.4)11.0 (3.5)15.4 (4.6)15.3 (4.8)Executive score, mean (SD) or median (IQR) ^b 21.4 (6.8)21.0 (6.6)7 (4-8)5 (3-8)	Alcohol consumption at least once per week	2654 (65.0)	2445 (47.3)	1745 (32.2)	160 (3.0)			
Coronary heart disease355 (8.7)245 (4.7)524 (9.7)739 (13.7)Stroke104 (2.5)118 (2.3)103 (1.9)86 (1.6)Cancer79 (1.9)100 (1.9)27 (0.5)64 (1.2)Chronic lung disease119 (2.9)118 (2.3)618 (11.4)431 (8.0)Asthma254 (6.2)446 (8.6)213 (3.9)138 (2.6)Memory score, mean (SD)10.3 (3.4)11.0 (3.5)15.4 (4.6)15.3 (4.8)Executive score, mean (SD) or median (IQR) ^b 21.4 (6.8)21.0 (6.6)7 (4-8)5 (3-8)	Hypertension	2350 (57.6)	2682 (51.8)	2035 (37.5)	2033 (37.7)			
Stroke 104 (2.5) 118 (2.3) 103 (1.9) 86 (1.6) Cancer 79 (1.9) 100 (1.9) 27 (0.5) 64 (1.2) Chronic lung disease 119 (2.9) 118 (2.3) 618 (11.4) 431 (8.0) Asthma 254 (6.2) 446 (8.6) 213 (3.9) 138 (2.6) Memory score, mean (SD) 10.3 (3.4) 11.0 (3.5) 15.4 (4.6) 15.3 (4.8) Executive score, mean (SD) or median (IQR) ^b 21.4 (6.8) 21.0 (6.6) 7 (4-8) 5 (3-8)	Diabetes	396 (9.7)	338 (6.5)	281 (5.2)	334 (6.2)			
Cancer79 (1.9)100 (1.9)27 (0.5)64 (1.2)Chronic lung disease119 (2.9)118 (2.3)618 (11.4)431 (8.0)Asthma254 (6.2)446 (8.6)213 (3.9)138 (2.6)Memory score, mean (SD)10.3 (3.4)11.0 (3.5)15.4 (4.6)15.3 (4.8)Executive score, mean (SD) or median (IQR)b21.4 (6.8)21.0 (6.6)7 (4-8)5 (3-8)	Coronary heart disease	355 (8.7)	245 (4.7)	524 (9.7)	739 (13.7)			
Chronic lung disease119 (2.9)118 (2.3)618 (11.4)431 (8.0)Asthma254 (6.2)446 (8.6)213 (3.9)138 (2.6)Memory score, mean (SD)10.3 (3.4)11.0 (3.5)15.4 (4.6)15.3 (4.8)Executive score, mean (SD) or median (IQR)b21.4 (6.8)21.0 (6.6)7 (4-8)5 (3-8)	Stroke	104 (2.5)	118 (2.3)	103 (1.9)	86 (1.6)			
Asthma 254 (6.2) 446 (8.6) 213 (3.9) 138 (2.6) Memory score, mean (SD) 10.3 (3.4) 11.0 (3.5) 15.4 (4.6) 15.3 (4.8) Executive score, mean (SD) or median (IQR) ^b 21.4 (6.8) 21.0 (6.6) 7 (4-8) 5 (3-8)	Cancer	79 (1.9)	100 (1.9)	27 (0.5)	64 (1.2)			
Memory score, mean (SD) 10.3 (3.4) 11.0 (3.5) 15.4 (4.6) 15.3 (4.8) Executive score, mean (SD) or median (IQR) ^b 21.4 (6.8) 21.0 (6.6) 7 (4-8) 5 (3-8)	Chronic lung disease	119 (2.9)	118 (2.3)	618 (11.4)	431 (8.0)			
Executive score, mean (SD) or median (IQR) ^b 21.4 (6.8) 21.0 (6.6) 7 (4-8) 5 (3-8)	Asthma	254 (6.2)	446 (8.6)	213 (3.9)	138 (2.6)			
	Memory score, mean (SD)	10.3 (3.4)	11.0 (3.5)	15.4 (4.6)	15.3 (4.8)			
Orientation score median (IOD) $A(A A) = A(A A) = A(2 A) = 2(2 A)$	Executive score, mean (SD) or median (IQR) ^b	21.4 (6.8)	21.0 (6.6)	7 (4-8)	5 (3-8)			
(2-4)	Orientation score, median (IQR)	4 (4-4)	4 (4-4)	4 (3-4)	3 (2-4)			

Abbreviations: CHARLS, China Health and Retirement Longitudinal Study; ELSA, English Longitudinal Study of Ageing; IQR, interquartile range.

^a Calculated as weight in kilograms divided by height in meters squared.

^b The executive scores are presented as mean (SD) for the ELSA and as median (IQR) for the CHARLS.

Table 2. Cross-Sectional Association Between Sleep Duration per Night and Global Cognitive Function at Baseline Using Analyses of Covariance

	ELSA (n = 9254)		CHARLS (n = 10811)		Pooled analysis (N = 20 065)			
Sleep duration per night, h	LSM (95% CI) of global z scores ^a	P value	LSM (95% CI) of global z scores ^a	P value	Pooled LSM (95% CI) of global z scores	P value ^b	l ² statistic, %	<i>P</i> value ^c
≤4	-0.19 (-0.28 to -0.09)	<.001	-0.19 (-0.25 to -0.12)	<.001	-0.19 (-0.24 to -0.13)	<.001	0.0	.99
5	-0.11 (-0.18 to -0.04)	.002	-0.02 (-0.08 to 0.04)	.55	-0.06 (-0.15 to 0.03)	.17	73.2	.05
6	-0.03 (-0.09 to 0.02)	.19	-0.01 (-0.06 to 0.05)	.78	-0.02 (-0.06 to 0.02)	.26	0.0	.48
7	1 [Reference]	NA	1 [Reference]	NA	1 [Reference]	NA	NA	NA
8	-0.09 (-0.14 to -0.05)	<.001	-0.07 (-0.12 to -0.01)	.01	-0.08 (-0.12 to -0.05)	<.001	0.0	.46
9	-0.22 (-0.31 to -0.14)	<.001	-0.21 (-0.31 to -0.11)	<.001	-0.22 (-0.28 to -0.15)	<.001	0.0	.84
≥10	-0.55 (-0.69 to -0.41)	<.001	-0.31 (-0.40 to -0.21)	<.001	-0.42 (-0.66 to -0.18)	.001	87.7	.004


Abbreviations: CHARLS, China Health and Retirement Longitudinal Study; ELSA, English Longitudinal Study of Ageing; LSM, least-squares means; NA, not applicable.

^a After adjusting for sex, age, body mass index, systolic blood pressure, level of education, Center for Epidemiologic Studies Depression Scale score, cohabitation status, current smoking, alcohol consumption, diabetes, coronary heart disease, stroke, cancer, chronic lung disease, and asthma.

Figure 1. Cross-sectional Associations Between Sleep Duration per Night and z Scores at Baseline

^b For the pooled LSM of global *z* scores.

^c For the *l*² statistic.



A-D, Participants who had a sleep duration of 7 hours per night served as the reference group. Solid lines represent adjusted least-squares means after adjusting for sex, age, body mass index, systolic blood pressure, level of education, Center for Epidemiologic Studies Depression Scale score, cohabitation status, current smoking, alcohol consumption, diabetes, coronary heart disease, stroke, cancer, chronic lung disease, and asthma. The shaded areas represent the 95% CIs. Detailed results are listed in Table 2 and eTables 1, 2, and 3 in the Supplement.

inverted U-shaped associations between baseline sleep duration and the 4 cognitive *z* scores were observed after adjusting for covariates. The individuals who slept 10 hours or more per night had the lowest cognitive scores (Figure 1).

Baseline Sleep Duration and Cognitive Decline Longitudinal Analyses

Table 3 lists the longitudinal results of the 2 cohorts and the pooled estimates of global cognitive decline. During 100 000 person-years of follow-up, global cognitive z scores in individuals with 4 hours or less (pooled β = -0.022; 95% CI, -0.035 to -0.009 SD per year; P = .001) and 10 hours or more (pooled β = -0.033; 95% Cl, -0.054 to -0.011 SD per year; P = .003) of sleep per night declined faster than in the reference group (7 hours per night) after adjusting for a number of covariates. The l^2 statistic indicated that no statistically significant heterogeneity between cohorts was observed (Table 3). An inverted U-shaped association between sleep duration and global cognitive decline, as well as memory, was observed (Figure 2) after adjusting for covariates. A sleep duration of 4 hours or less was statistically significantly associated with faster orientation decline (pooled $\beta = -0.019$; 95% CI, -0.034 to -0.004 SD per year; P = .01) but not decline in memory (pooled β = -0.021; 95% CI, -0.045 to 0.003 SD per year; P = .09) or executive function (pooled β = 0.000; 95% CI, -0.042 to 0.043 SD per year; P > .99) (Figure 2 and eTables 4, 5, and 6 in the Supplement). Associations between sleep duration of 10 hours or more and single domains did not achieve statistical significance for memory (pooled $\beta = -0.022$; 95% CI, -0.052 to 0.007 SD per year; P = .14), executive function (pooled $\beta = -0.001$; 95% Cl, -0.023 to 0.022 SD per year; P = .96), or orientation (pooled β = -0.019; 95% Cl, -0.044 to 0.005 SD per year; P = .12) (Figure 2 and eTables 4, 5, and 6 in the Supplement).

Nonresponse Analyses

From the baseline population, 1215 of 10 469 individuals (11.6%) from the ELSA and 1264 of 12 075 individuals (10.5%) from the CHARLS were excluded from the analyses because of loss to follow-up. In both cohorts, compared with the included participants, the excluded participants were older, had higher systolic blood pressure, were more likely to live alone, were less likely to engage in alcohol consumption, had higher rates of self-reported coronary heart disease and stroke, and had lower memory and orientation scores at baseline (eTables 7 and 8 in the Supplement).

Sensitivity Analyses

To assess the potential impact of participant sex on the main results, separate analyses were performed by sex. The results also showed an inverted U-shaped association between sleep duration and global cognitive function and a subsequent decline in both men and women, similar to the main analyses. However, some associations, especially those in the longitudinal analyses, were no longer statistically significant for single domains (eTables 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, and 24 and eFigures 2, 3, 4, and 5 in the Supplement).

Discussion

In this pooled cohort study of large groups from the ELSA and the CHARLS, a statistically significant inverted U-shaped association was observed between sleep duration and cognitive function. We also found that extreme sleep duration at baseline, including 4 hours or less or 10 hours or more per night, was statistically significantly associated with faster cognitive decline during 100 000 person-years of follow-up. These findings were consistent in both the ELSA and the CHARLS despite the substantial cultural and racial/ethnic differences. To the best of our knowledge, the present study is one of the largest cohort studies to analyze the association between sleep duration and subsequent cognitive decline by combining 2 nationally representative aging cohorts.


Previous studies⁷⁻²⁴ have investigated the longitudinal association between sleep duration and cognitive decline or dementia. Tworoger et al¹² analyzed data from the US Nurses' Health Study.


Sleep duration per night, h	ELSA (n = 9254)		CHARLS (n = 10811)		Pooled analysis (N = 20 065)			
	β (95% Cl) ^a	P value	β (95% Cl) ^a	P value	Pooled β (95% Cl)	P value ^b	I ² statistic, %	P value ^c
≤4	-0.021 (-0.038 to -0.003)	.02	-0.024 (-0.044 to -0.003)	.02	-0.022 (-0.035 to -0.009)	.001	0	.83
5	-0.004 (-0.018 to 0.009)	.51	-0.007 (-0.028 to 0.014)	.51	-0.005 (-0.017 to 0.006)	.37	0	.84
6	-0.005 (-0.015 to 0.005)	.33	-0.003 (-0.022 to 0.015)	.71	-0.005 (-0.013 to 0.004)	.30	0	.89
7	1 [Reference]	NA	1 [Reference]	NA	1 [Reference]	NA	NA	NA
8	-0.004 (-0.012 to 0.005)	.45	-0.001 (-0.020 to 0.017)	.88	-0.003 (-0.011 to 0.005)	.45	0	.85
9	-0.023 (-0.041 to -0.006)	.007	0.009 (-0.025 to 0.042)	.61	-0.011 (-0.042 to 0.020)	.49	64.4	.09
≥10	-0.030 (-0.059 to -0.001)	.05	-0.036 (-0.068 to -0.004)	.03	-0.033 (-0.054 to -0.011)	.003	0	.78

Table 3. Mean Difference in Rate of Change in Global Cognitive Decline (SD per Year) During Follow-up Using Linear Mixed Models

Abbreviations: CHARLS, China Health and Retirement Longitudinal Study; ELSA, English^b For the pooled β.Longitudinal Study of Ageing; NA, not applicable.^c For the l² statistic.

^a After adjusting for sex, age, body mass index, systolic blood pressure, level of education, Center for Epidemiologic Studies Depression Scale score, cohabitation status, current smoking, alcohol consumption, diabetes, coronary heart disease, stroke, cancer, chronic lung disease, and asthma.





A-D, Participants who had a sleep duration of 7 hours per night served as the reference group. Solid lines represent adjusted mean differences after adjusting for sex, age, body mass index, systolic blood pressure, level of education, Center for Epidemiologic Studies Depression Scale score, cohabitation status, current smoking, alcohol consumption,

diabetes, coronary heart disease, stroke, cancer, chronic lung disease, and asthma. The shaded areas represent the 95% CIs. Detailed results are listed in Table 3 and eTables 4, 5, and 6 in the Supplement.

However, they found no association between sleep duration and cognitive function, likely because of the short follow-up period (2 years) and limited sample size (n = 1884). Virta et al⁷ analyzed data from the Finnish Twin Cohort in 2013 and noted that individuals with long (>8 hours per day) or short (<7 hours per day) sleep duration at baseline had lower subsequent cognitive test scores. Although similar findings have been reported by other researchers, ^{8,9,11} some studies¹²⁻²⁴ do not support this conclusion. Most of these previous studies were conducted using sample sizes of less than 1000 individuals, ^{14,15,19,20,22,24} samples of only 1 sex, ^{8,9,12,14,17,18} or less than 3 years of follow-up.^{12,16,21} Only 2 studies^{8,10} included more than 10 000 individuals, and both revealed inverted U-shaped associations between sleep duration and subsequent cognitive decline, as well as incident dementia, which is in agreement with the present study. However, these 2 studies were weak in representativeness because they used an all-female cohort⁸ and a twin cohort.¹⁰

In the present longitudinal study, a differential association was detected between sleep duration and distinct cognitive aspects, and memory was the main cognitive domain altered among the 3 domains measured. Memory impairment is the core symptom of dementia and can be considered a factor in the conversion from mild cognitive impairment to dementia.⁴² Previous studies have indicated that acute sleep deprivation impairs memory encoding and consolidation^{43,44} and that short sleep duration is associated with an increase in the risk of developing memory deficits.⁴⁵ Moreover, epidemiological studies^{46,47} have found that long sleep duration is statistically significantly associated with memory deficits in both middle-aged adults and older participants, even after controlling for comorbidities, anxiety, and depression. These data suggest that memory may be altered by changes in sleep habits.

The mechanisms underlying the association between sleep duration and cognitive decline remain unclear, although several plausible biological pathways have been identified. Although the cerebral cortex normally thins with age, a longitudinal study⁴⁸ reported an association between sleep durations of more or less than 7 hours and increased cortical thinning in the frontotemporal areas among cognitively normal older adults. Patel et al⁴⁹ suggested that activity in the interleukin 6 and C-reactive protein inflammatory pathways could be elevated by excessive sleep duration, and they reported a linear association between interleukin 6, C-reactive protein, and sleep duration. Furthermore, inflammatory disorders have been shown to mediate age-related cognitive impairment.⁵⁰

With respect to short sleep duration, long-term fatigue might be an intermediate variable impacting cognitive decline.⁵¹ Brief periods of sleep deprivation have been associated with an increase in hippocampal synaptic plasticity, contributing to subsequent impaired cognitive function.⁵² The amyloid cascade hypothesis that regards the deposition of amyloid plaques as a crucial event for the etiology of Alzheimer disease might explain the underlying mechanism of sleep deprivation-induced impairment. A randomized clinical trial⁵³ in healthy middle-aged men indicated that even 1 night of sleep deprivation could elevate cerebrospinal fluid levels of Aβ42 protein. Tau, a microtubule-associated protein and another accelerator of Alzheimer disease-related neurodegeneration, has also been found to increase by 50% in human cerebrospinal fluid and by 100% in mouse interstitial fluid during chronic sleep deprivation.⁵⁴

Strengths and Limitations

The foremost strength of the present study is that an association between sleep duration and cognitive function was detected in 2 large cohorts from different cultures. That our findings were consistent across 2 nationally representative community-based cohorts enhances the generalizability of the data, and the large sample size enables more certainty in our statistical analysis. Fortunately, these 2 cohorts shared the exact same measurement methods for sleep duration, memory, and orientation, which facilitated the pooled analyses. Second, the participants in both cohorts were asked about sleep duration without being given durations to choose from, which was not the case in some prior studies.^{8,9,12} This approach, combined with the large population sizes, contributed to the identification of a reliable association between extreme sleep duration and

cognitive decline. In addition, no statistically significant heterogeneity between cohorts was observed in the longitudinal analyses for global cognitive function, indicating that the results from the ELSA and the CHARLS were comparable.

This study has several limitations. First, this investigation was an observational study, so no causal relationships could be demonstrated. There is a possibility of reverse causality. Excessive or short sleep duration might be an early manifestation of brain impairment. Furthermore, individuals with memory impairment might not accurately remember their sleep duration. Second, similar to most of the previous studies, 7-13,15,16,19-23 sleep duration was obtained according to self-reported information rather than objective measurement, which might have resulted in random misclassification and may have biased the results toward the null. Third, selection bias may have occurred because 1215 individuals (11.6%) from the ELSA and 1264 individuals (10.5%) from the CHARLS were excluded from the study because of loss to follow-up. The results from the nonresponse analyses indicate that our study samples were healthier than the initial samples from the ELSA and the CHARLS. However, loss to follow-up of less than 20% of the overall sample is not considered to imply the presence of considerable bias, even when the missing participants are not missing at random.⁵⁵ Fourth, although we adjusted for a number of confounding factors in our analyses, unmeasured covariates might still have led to confounding bias, including APOE status, other sleep disorders, and medication use. Fifth, cognitive function was measured in both cohorts using isolated tasks. These might not have been sufficiently sensitive to detect subtle declines in cognitive function over the follow-up period, thus biasing the results toward the null.

Conclusions

A statistically significant inverted U-shaped association was observed between sleep duration and cognitive function, as well as subsequent decline. Extreme sleep duration (ie, \leq 4 or \geq 10 hours per night) was associated not only with lower cognitive function at baseline but also with faster cognitive decline during the follow-up assessments. The inverted U-shaped association indicates that cognitive function should be monitored in middle-aged and older individuals with insufficient or excessive sleep duration. Future mechanism studies and intervention studies examining the association between sleep duration and cognitive decline are needed.

ARTICLE INFORMATION

Accepted for Publication: June 2, 2020.

Published: September 21, 2020. doi:10.1001/jamanetworkopen.2020.13573

Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2020 Ma Y et al. *JAMA Network Open.*

Corresponding Author: Wuxiang Xie, PhD, Peking University Clinical Research Institute, Peking University First Hospital, 8 Xishiku St, Xicheng District, Beijing 100034, China (xiewuxiang@hsc.pku.edu.cn).

Author Affiliations: Peking University Clinical Research Institute, Peking University First Hospital, Beijing, China (Ma, Xie); Clinical Epidemiology Department, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China (Liang); Brainnetome Center, Institute of Automation, Chinese Academy of Sciences, Beijing (Zheng); National Clinical Research Center for Mental Disorders, Key Laboratory of Mental Health and Peking University Sixth Hospital, Peking University, Beijing, China (Shi); Department of Geriatric Psychiatry, Affiliated Wuhan Mental Health Center, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China (Zhong).

Author Contributions: Mr Ma and Dr Liang contributed equally to this work. Dr Xie had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Ma, Liang, Shi, Zhong, Xie.

Acquisition, analysis, or interpretation of data: Ma, Liang, Zheng, Zhong, Xie.

Drafting of the manuscript: Ma, Liang, Zheng, Xie.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Ma, Liang, Zhong, Xie.

Obtained funding: Liang, Xie.

Administrative, technical, or material support: Zheng, Xie.

Supervision: Shi, Xie.

Conflict of Interest Disclosures: None reported.

Funding/Support: This work was supported by the National Natural Science Foundation of China (project 81974490), the Newton International Fellowship from the Academy of Medical Sciences (project NIF001-1005-P56804), the Fundamental Research Funds for the Central Universities of China (project 71006Y2205), and the 2019 Irma and Paul Milstein Program for Senior Health Research Project Award.

Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: We thank Sydney Koke, MFA, from Edanz Group (www.edanzediting.com/ac) for editing a draft of the manuscript. She was compensated for her contributions. We thank the original data creators, depositors, copyright holders, and funders of the data collections for the use of data from the English Longitudinal Study of Ageing (waves 4-8) and the China Health and Retirement Longitudinal Study (waves 1-3).

REFERENCES

1. United Nations Department of Economic and Social Affairs. Population Division. *World Population Prospects: The 2015 Revision: Key Findings and Advance Tables.* United Nations Working Paper ESA/P/WP.241. Accessed August 12, 2020. https://population.un.org/wpp/Publications/Files/Key_Findings_WPP_2015.pdf

2. Prince M, Comas-Herrera A, Knapp M, Guerchet M, Karagiannidou M. *World Alzheimer Report 2016: Improving Healthcare for People Living With Dementia: Coverage, Quality and Costs Now and in the Future*. Alzheimer's Disease International. September 2016. Accessed August 12, 2020. https://www.alz.co.uk/research/ WorldAlzheimerReport2016.pdf

3. Alzheimer's Association. 2018 Alzheimer's disease facts and figures. *Alzheimers Dement*. 2018;14(3):367-429. doi:10.1016/j.jalz.2018.02.001

4. Plassman BL, Langa KM, Fisher GG, et al. Prevalence of dementia in the United States: the Aging, Demographics, and Memory Study. *Neuroepidemiology*. 2007;29(1-2):125-132. doi:10.1159/000109998

5. Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care. *Lancet*. 2017;390 (10113):2673-2734. doi:10.1016/S0140-6736(17)31363-6

6. Shi L, Chen SJ, Ma MY, et al. Sleep disturbances increase the risk of dementia: a systematic review and metaanalysis. *Sleep Med Rev.* 2018;40:4-16. doi:10.1016/j.smrv.2017.06.010

7. Virta JJ, Heikkilä K, Perola M, et al. Midlife sleep characteristics associated with late life cognitive function. *Sleep.* 2013;36(10):1533-1541, 1541A. doi:10.5665/sleep.3052

8. Devore EE, Grodstein F, Duffy JF, Stampfer MJ, Czeisler CA, Schernhammer ES. Sleep duration in midlife and later life in relation to cognition. *J Am Geriatr Soc.* 2014;62(6):1073-1081. doi:10.1111/jgs.12790

9. Chen JC, Espeland MA, Brunner RL, et al. Sleep duration, cognitive decline, and dementia risk in older women. *Alzheimers Dement*. 2016;12(1):21-33. doi:10.1016/j.jalz.2015.03.004

10. Bokenberger K, Ström P, Dahl Aslan AK, et al. Association between sleep characteristics and incident dementia accounting for baseline cognitive status: a prospective population-based study. *J Gerontol A Biol Sci Med Sci*. 2017; 72(1):134-139. doi:10.1093/gerona/glw127

11. Ohara T, Honda T, Hata J, et al. Association between daily sleep duration and risk of dementia and mortality in a Japanese community. *J Am Geriatr Soc.* 2018;66(10):1911-1918. doi:10.1111/jgs.15446

12. Tworoger SS, Lee S, Schernhammer ES, Grodstein F. The association of self-reported sleep duration, difficulty sleeping, and snoring with cognitive function in older women. *Alzheimer Dis Assoc Disord*. 2006;20(1):41-48. doi: 10.1097/01.wad.0000201850.52707.80

13. Benito-León J, Bermejo-Pareja F, Vega S, Louis ED. Total daily sleep duration and the risk of dementia: a prospective population-based study. *Eur J Neurol*. 2009;16(9):990-997. doi:10.1111/j.1468-1331.2009.02618.x

14. Yaffe K, Laffan AM, Harrison SL, et al. Sleep-disordered breathing, hypoxia, and risk of mild cognitive impairment and dementia in older women. *JAMA*. 2011;306(6):613-619. doi:10.1001/jama.2011.1115

15. Keage HAD, Banks S, Yang KL, Morgan K, Brayne C, Matthews FE. What sleep characteristics predict cognitive decline in the elderly? *Sleep Med*. 2012;13(7):886-892. doi:10.1016/j.sleep.2012.02.003

16. Potvin O, Lorrain D, Forget H, et al. Sleep quality and 1-year incident cognitive impairment in communitydwelling older adults. *Sleep*. 2012;35(4):491-499. doi:10.5665/sleep.1732

17. Blackwell T, Yaffe K, Laffan A, et al; Osteoporotic Fractures in Men (MrOS) Study Group. Associations of objectively and subjectively measured sleep quality with subsequent cognitive decline in older community-dwelling men: the MrOS sleep study. *Sleep*. 2014;37(4):655-663. doi:10.5665/sleep.3562

18. Diem SJ, Blackwell TL, Stone KL, et al. Measures of sleep-wake patterns and risk of mild cognitive impairment or dementia in older women. *Am J Geriatr Psychiatry*. 2016;24(3):248-258. doi:10.1016/j.jagp.2015.12.002

19. Johar H, Kawan R, Emeny RT, Ladwig KH. Impaired sleep predicts cognitive decline in old people: findings from the prospective KORA Age Study. *Sleep*. 2016;39(1):217-226. doi:10.5665/sleep.5352

20. Lutsey PL, Bengtson LGS, Punjabi NM, et al. Obstructive sleep apnea and 15-year cognitive decline: the Atherosclerosis Risk in Communities (ARIC) study. *Sleep*. 2016;39(2):309-316. doi:10.5665/sleep.5434

21. Niu J, Han H, Wang Y, Wang L, Gao X, Liao S. Sleep quality and cognitive decline in a community of older adults in Daqing City, China. *Sleep Med*. 2016;17:69-74. doi:10.1016/j.sleep.2015.07.033

22. Sindi S, Kåreholt I, Johansson L, et al. Sleep disturbances and dementia risk: a multicenter study. *Alzheimers Dement*. 2018;14(10):1235-1242. doi:10.1016/j.jalz.2018.05.012

23. Suh SW, Han JW, Lee JR, et al. Sleep and cognitive decline: a prospective nondemented elderly cohort study. *Ann Neurol.* 2018;83(3):472-482. doi:10.1002/ana.25166

24. McSorley VE, Bin YS, Lauderdale DS. Associations of sleep characteristics with cognitive function and decline among older adults. *Am J Epidemiol.* 2019;188(6):1066-1075. doi:10.1093/aje/kwz037

25. Steptoe A, Breeze E, Banks J, Nazroo J. Cohort profile: the English Longitudinal Study of Ageing. *Int J Epidemiol*. 2013;42(6):1640-1648. doi:10.1093/ije/dys168

26. Zhao Y, Hu Y, Smith JP, Strauss J, Yang G. Cohort profile: the China Health and Retirement Longitudinal Study (CHARLS). Int J Epidemiol. 2014;43(1):61-68. doi:10.1093/ije/dys203

27. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. *JAMA*. 2013;310(20):2191-2194. doi:10.1001/jama.2013.281053

28. Marmot M, Oldfield Z, Clemens S, et al. English Longitudinal Study of Ageing: Waves O-7, 1998-2015. 27th ed. UK Data Service; 2017.

29. Mindell J, Biddulph JP, Hirani V, et al. Cohort profile: the Health Survey for England. *Int J Epidemiol*. 2012;41 (6):1585-1593. doi:10.1093/ije/dyr199

30. Dregan A, Stewart R, Gulliford MC. Cardiovascular risk factors and cognitive decline in adults aged 50 and over: a population-based cohort study. *Age Ageing*. 2013;42(3):338-345. doi:10.1093/ageing/afs166

31. Levine DA, Galecki AT, Langa KM, et al. Trajectory of cognitive decline after incident stroke. *JAMA*. 2015;314 (1):41-51. doi:10.1001/jama.2015.6968

32. Xu H, Zhang Z, Li L, Liu J. Early life exposure to China's 1959-61 famine and midlife cognition. *Int J Epidemiol*. 2018;47(1):109-120. doi:10.1093/ije/dyx222

33. Zheng F, Yan L, Yang Z, Zhong B, Xie W. HbA_{1c}, diabetes and cognitive decline: the English Longitudinal Study of Ageing. *Diabetologia*. 2018;61(4):839-848. doi:10.1007/s00125-017-4541-7

34. Xie W, Zheng F, Yan L, Zhong B. Cognitive decline before and after incident coronary events. *J Am Coll Cardiol*. 2019;73(24):3041-3050. doi:10.1016/j.jacc.2019.04.019

35. Cacioppo JT, Hughes ME, Waite LJ, Hawkley LC, Thisted RA. Loneliness as a specific risk factor for depressive symptoms: cross-sectional and longitudinal analyses. *Psychol Aging*. 2006;21(1):140-151. doi:10.1037/0882-7974.21.1.140

36. Zheng F, Zhong B, Song X, Xie W. Persistent depressive symptoms and cognitive decline in older adults. *Br J Psychiatry*. 2018;213(5):638-644. doi:10.1192/bjp.2018.155

37. Hamer M, Batty GD, Kivimaki M. Risk of future depression in people who are obese but metabolically healthy: the English Longitudinal Study of Ageing. *Mol Psychiatry*. 2012;17(9):940-945. doi:10.1038/mp.2012.30

38. Li C, Miles T, Shen L, et al. Early-life exposure to severe famine and subsequent risk of depressive symptoms in late adulthood: the China Health and Retirement Longitudinal Study. *Br J Psychiatry*. 2018;213(4):579-586. doi: 10.1192/bjp.2018.116

39. Chen H, Mui AC. Factorial validity of the Center for Epidemiologic Studies Depression Scale short form in older population in China. *Int Psychogeriatr.* 2014;26(1):49-57. doi:10.1017/S1041610213001701

40. UK Data Service. English Longitudinal Study of Ageing. Accessed October 2019. https://beta.ukdataservice.ac. uk/datacatalogue/series/series?id=200011

41. CHARLS. China Health and Retirement Longitudinal Study. Accessed October 2019. http://charls.pku.edu.cn

42. Lee M, Lim TS, Lee HY, Moon SY. Profile of memory impairment as a prognostic marker in amnestic mild cognitive impairment. *J Neurol Sci.* 2014;347(1-2):124-128. doi:10.1016/j.jns.2014.09.031

43. Cousins JN, Sasmita K, Chee MWL. Memory encoding is impaired after multiple nights of partial sleep restriction. *J Sleep Res.* 2018;27(1):138-145. doi:10.1111/jsr.12578

44. Alger SE, Chambers AM, Cunningham T, Payne JD. The role of sleep in human declarative memory consolidation. *Curr Top Behav Neurosci*. 2015;25:269-306. doi:10.1007/7854_2014_341

45. Xu L, Jiang CQ, Lam TH, et al. Sleep duration and memory in the elderly Chinese: longitudinal analysis of the Guangzhou Biobank Cohort Study. *Sleep*. 2014;37(11):1737-1744. doi:10.5665/sleep.4162

46. Tsapanou A, Gu Y, O'Shea DM, et al. Sleep quality and duration in relation to memory in the elderly: initial results from the Hellenic Longitudinal Investigation of Aging and Diet. *Neurobiol Learn Mem.* 2017;141:217-225. doi:10.1016/j.nlm.2017.04.011

47. van Oostrom SH, Nooyens ACJ, van Boxtel MPJ, Verschuren WMM. Long sleep duration is associated with lower cognitive function among middle-age adults: the Doetinchem Cohort Study. *Sleep Med*. 2018;41:78-85. doi: 10.1016/j.sleep.2017.07.029

48. Spira AP, Gonzalez CE, Venkatraman VK, et al. Sleep duration and subsequent cortical thinning in cognitively normal older adults. *Sleep*. 2016;39(5):1121-1128. doi:10.5665/sleep.5768

49. Patel SR, Zhu X, Storfer-Isser A, et al. Sleep duration and biomarkers of inflammation. *Sleep*. 2009;32(2): 200-204. doi:10.1093/sleep/32.2.200

50. Lin T, Liu GA, Perez E, et al. Systemic inflammation mediates age-related cognitive deficits. *Front Aging Neurosci.* 2018;10:236. doi:10.3389/fnagi.2018.00236

51. Ohayon MM, Vecchierini MF. Normative sleep data, cognitive function and daily living activities in older adults in the community. *Sleep*. 2005;28(8):981-989.

52. Vecsey CG, Baillie GS, Jaganath D, et al. Sleep deprivation impairs cAMP signalling in the hippocampus. *Nature*. 2009;461(7267):1122-1125. doi:10.1038/nature08488

53. Ooms S, Overeem S, Besse K, Rikkert MO, Verbeek M, Claassen JA. Effect of 1 night of total sleep deprivation on cerebrospinal fluid β -amyloid 42 in healthy middle-aged men: a randomized clinical trial. *JAMA Neurol*. 2014;71 (8):971-977. doi:10.1001/jamaneurol.2014.1173

54. Holth JK, Fritschi SK, Wang C, et al. The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans. *Science*. 2019;363(6429):880-884. doi:10.1126/science.aav2546

55. Kristman V, Manno M, Côté P. Loss to follow-up in cohort studies: how much is too much? *Eur J Epidemiol*. 2004;19(8):751-760. doi:10.1023/B:EJEP.0000036568.02655.f8

SUPPLEMENT.

eMethods. Supplemental Methods

eTable 1. Association Between Sleep Duration per Night and Memory Function at Baseline

eTable 2. Association Between Sleep Duration per Night and Executive Function at Baseline

eTable 3. Association Between Sleep Duration per Night and Orientation Function at Baseline

eTable 4. Association Between Sleep Duration and Memory Decline (SD/year) During Follow-up

eTable 5. Association Between Sleep Duration and Executive Decline (SD/year) During Follow-up

eTable 6. Association Between Sleep Duration and Orientation Decline (SD/year) During Follow-up

eTable 7. Comparison of Baseline Characteristics Between Participants Included (n = 9254) and Excluded From the ELSA, Due to Loss to Follow-up (n = 1215)

eTable 8. Comparison of Baseline Characteristics Between the Participants Included (n = 10 811) and Excluded From the CHARLS Due to Loss to Follow-up (n = 1264)

eTable 9. Association Between Sleep Duration per Night and Global Cognitive Function at Baseline in Men

eTable 10. Association Between Sleep Duration per Night and Memory Function at Baseline in Men

eTable 11. Association Between Sleep Duration per Night and Executive Function at Baseline in Men

eTable 12. Association Between Sleep Duration per Night and Orientation Function at Baseline in Men

eTable 13. Association Between Sleep Duration per Night and Global Cognitive Function at Baseline in Women

eTable 14. Association Between Sleep Duration per Night and Memory Function at Baseline in Women

eTable 15. Association Between Sleep Duration per Night and Executive Function at Baseline in Women

eTable 16. Association Between Sleep Duration per Night and Orientation Function at Baseline in Women eTable 17. Association Between Sleep Duration and Global Cognitive Decline (SD/y) During Follow-up in Men

eTable 18. Association Between Sleep Duration and Memory Decline (SD/year) During Follow-up in Men

eTable 19. Association Between Sleep Duration and Executive Decline (SD/year) During Follow-up in Men

eTable 20. Association Between Sleep Duration and Orientation Decline (SD/year) During Follow-up in Men eTable 21. Association Between Sleep Duration and Global Cognitive Decline (SD/y) During Follow-up in Women eTable 22. Association Between Sleep Duration and Memory Decline (SD/year) During Follow-up in Women eTable 23. Association Between Sleep Duration and Executive Decline (SD/year) During Follow-up in Women eTable 24. Association Between Sleep Duration and Orientation Decline (SD/year) During Follow-up in Women eTable 24. Association Between Sleep Duration and Orientation Decline (SD/year) During Follow-up in Women eFigure 1. Flow Chart of Participant Selection for This Study

eFigure 2. Cross-sectional Associations Between Sleep Duration per Night and Cognitive Functions at Baseline in Men

eFigure 3. Cross-sectional Associations Between Sleep Duration per Night and Cognitive Functions at Baseline in Women

eFigure 4. Longitudinal Associations Between Sleep Duration per Night and Cognitive Declines During Follow-up in Men

eFigure 5. Longitudinal Associations Between Sleep Duration per Night and Cognitive Declines During Follow-up in Women